Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.

The beloved radio presenter was first diagnosed in 2000, and doctors predicted he had three months to live before he ...

James Whale, a longtime radio and television host from Britain, has died at age 74. His death was announced on August 4, 2025 ...

Kidney cancer risks, symptoms, treatment, and prevention, including the benefits of robotic-assisted surgery for optimal ...

What if a computer could read a patient's medical notes and help doctors determine important information for their treatment?

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tum ...